Filed with ASX · · 9 pages · English
The report highlights the company's decision to manufacture a demonstration batch of its compound AOC, which is aimed at assisting weight reduction. The company continues to explore opportunities related to its GaRP project and other strategic directions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
_________________________________________________________________________________ ASX Release Anatara Lifesciences 4C & Q1 FY27 Activities Report Highlights for the Quarter ending September 2026 • Anti-Obesity project to be progressed with manufacturing of a demonstration batch of...
Anatara Lifesciences Ltd on 6ix
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences